GenomSys SA

ENABLE Biotech aims to partner with companies from research to clinical stage to address specific challenges of manufacturing Advanced Therapies. Our next generation CDMO model enables an attractive pricing structure and expertise in CMC for speed to Phase I/IIa.

HekeTiss, a UNIGE/HUG spin-off, enhances lives by pioneering cell-therapy treatments for ulcerative skin conditions. Innovating for a healthier tomorrow.

FatiAbGen International is the Swiss subsidiary of FatiAbGen Co. Ltd., established in Korea in 2020. We engineer best in class antibodies tailored for multiple modalities such as ADCs and bi-specifics. We then develop targeted molecules to address high unmet need diseases in oncology and immunology.